Bio/Pharma News
EMA Validates Parallel Applications for Datopotamab Deruxtecan in Two Types of Cancer
EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.
J&J Completes $2 Billion Ambrx Acquisition, Boosts Pipeline for Next-Gen ADCs
Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.
Cellares Innovates With Automated Cell and Gene Therapy Platform
Cellares CEO Fabian Gerlinghaus shares how an automated, closed-production platform with a small footprint can dramatically impact cost savings and scalability for cell and gene therapies.
AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation
Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.
Nona Biosciences Partners with Boostimmune on ADC Development
Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.
AstraZeneca Completes Acquisition of Icosavax
AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.
GSK Seeks to Expand its Respiratory Biologics Portfolio with Aiolos Acquisition
GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.
FDA Approves Amtagvi, First Cell Therapy for Skin Cancer
FDA has approved Iovance Biotherapeutics’ Amtagvi (lifileucel) for treating patients with unresectable or metastatic melanoma.
BioVaxys Acquires Full Portfolio of Former IMV
BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.
Novartis to Acquire MorphoSys for Roughly $2.9 Billion
Through a €2.7 billion (US$2.9 billion) acquisition of MorphoSys, Novartis will get pelabresib, a late-stage drug candidate in development for cancer treatment.
Regeneron Forms R&D Cell Therapy Unit from 2seventy bio Platform Acquisition
With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.
FDA Grants Orphan Drug Designation to First-in-Class Treatment for Eosinophilic Esophagitis
The immune-resetting peptide, developed by Revolo Biotherapeutics, received positive results from its Phase IIb study.
IMU Biosciences Raises Millions in Series A Funding Round
IMU Biosciences has secured £11.5 million in its Series A financing round.
Sanofi to Aquire Inhibrx for $1.7 Billion
The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.
Takeda’s Subcutaneous Immunoglobulin Receives FDA Approval for Maintenance Therapy of Rare Neuromuscular Disorder
Takeda has received FDA approval for HYQVIA, a subcutaneous immunoglobulin for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy.
Merck to Acquire Harpoon Therapeutics in Deal Valued at $680 Million
Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.
AI Biotech Secures Funding to Speed Up Stem Cell Therapy Development
CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.
Boehringer Ingelheim Expands Facility in Greece for Production of New Therapeutics
Boehringer Ingelheim is investing €120 million (US$131 million) into its Koropi, Greece site to expand production for new therapeutics.
GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio
In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.
Leiters Health Recalls Vancomycin IV Bags, Phenylephrine IV Bags, and Fentanyl IV Bags
The potential for superpotent drug initiated the voluntary recall.
DoD Grants Additional Funds to MediWound for Advancement of Non-Surgical Treatment for Field Care Burns
MediWound has been granted an additional $6.7 million by the DoD to advance NexoBrid as a non-surgical field care solution for the US military.
Boehringer Ingelheim and Ribo Partner on RNA-based Liver Disease Therapeutics
Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH.
Roche to Acquire Point-of-Care Technology from LumiraDx in $350 Million Deal
Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument.
AstraZeneca Poised to Acquire Cell Therapy Developer, Gracell, in Deal Valued at $1.2 Billion
AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.
QurAlis Opens European Headquarters in The Netherlands
The new Europe headquarters will be the hub for the company’s European operations, including production of product.
AstraZeneca to Acquire Icosavax in Deal Valued at Approximately $1.1 Billion
With the acquisition, AstraZeneca will gain a potential RSV and hMPV combination vaccine.
Replay Signs Exclusive Licensing Agreements with NIH and Miltenyi Biotec for Cell Therapy Development and Manufacturing
Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec.
Ultragenyx Picks Andelyn Biosciences to Manufacture Novel Gene Therapy for Sanfilippo Syndrome
Andelyn Biosciences has been selected by Ultragenyx to manufacture UX111, that company’s gene therapy for treating Sanfilippo Syndrome.
Daiichi Sankyo Partners with Depixus to Accelerate RNA-Targeted Drug Discovery
Under a collaboration, Daiichi Sankyo and Depixus will use Depixus’ MAGNA technology to accelerate drug discovery efforts of RNA-targeted therapeutics.
Bristol Myers Squibb and SystImmune Enter Global ADC Collaboration Worth Potentially up to $8.4 Billion
Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.
